Skip To Main Content
Orla Hardiman on Muck Rack

Orla Hardiman

As seen in: Color Research & Application, Nature, BMJ Open, The Conversation, The Irish Times, RTÉ, BioRxiv, The Lancet, Future Medicine, The Medical Independent and
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Orla

Contact Orla, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

Longitudinal cognitive assessment using the Cumulus NeuLogiq platform in amyotrophic lateral sclerosis and frontotemporal dementia

|
By Ciara Brennan, Sophie Leonard, Mark Heverin, Florentine M. Barbey, John Dyer Verified, Laura M. Rueda-Delgado, Elizabeth M. Tunbridge, Hugh M. Marston, Richard Hargreaves, Viet ThiThuy NGUYEN, Ann Marie Hake, Gerard Dawson, Robert D. Latzman, Brian Murphy Verified, Orla Hardiman, Niall Pender, Emmet Costello, Kimberly Kiyui, Niamh Ni Obain, Shannon Diggin, Robert Y.K. Lai, Leslie Shinobu, Alison Buick
| Nature Verified
Abstract People living with ALS (plwALS) and/or FTD (plwFTD) often experience cognitive and behavioural changes. However, detection can be confounded due to factors like fatigue and testing anxiety. Cumulus neuroscience developed NeuLogiq(R), a multi-modal neurocognitive platform that can be used in clinic or at home, providing an ecologically valid measure of cognition.
Open in Who Shared Issue with article?

Amyotrophic lateral sclerosis: a lesson in translation

|
By Orla Hardiman
| The Lancet Verified
The management of amyotrophic lateral sclerosis (ALS) is in the spotlight as trial results are published and regulatory decisions on therapies are made. In Europe, the antisense oligonucleotide tofersen, which targets mutations in the SOD1 gene, is expected to be approved in 2024 by the European Medicines Agency and is under review by the UK National Institute for Health and Care Excellence ( NICE ).
Open in Who Shared Issue with article?

Recognising Brain Awareness

|
By Orla Hardiman, Aoife Jackson
| Hospital Professional News
National Brain Awareness Week is an annual initiative organized in March each year by the Neurological Alliance of Ireland to promote greater awareness and understanding of the impact of living with a neurological condition as well as the need for investment in services, research and prevention. The Neurological Alliance of Ireland is the national umbrella group for neurological charities.
Open in Who Shared Issue with article?
See all 18 licensed articles (22 Total)